Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
@Gijpie: hoe gaat het spreekwoord al weer? Vertrouwen komt te voet en gaat te paard ... ik vrees dat BCART een paar serieuze bevestiging nodig heeft voordat ze het vertrouwen weer kunnen herstellen.
ImmunExpress snags a grant to help roll out Septicyte Rapid in Australia. PR is sneaky in how it mentions that the grant institution has a $400 million budget while not mentioning the size of the grant. FLwww.medianet.com.au/releases/release-...
@ Flat. For someone who is prepared to take a little gamble Tonix Pharmaceuticals on the Nasdaq . Their lead vaccine candidate against Covid 19 seems to have impressive efficacitie on animals. If they could optain a fast NDA this could be a big winner. They seem to be convinced because they plan on building 2 big factory’s to produce . Any thougts on this one Flat
@ Pumske Ik ben nog maar sinds kort een poging aan het doen om de wereld van het beleggen wat beter te begrijpen. En van de link die je deelde begrijp ik al helemaal niet veel.. Iemand die misschien een beetje uitleg kan geven?
@ Mil Studie over het belang van PCR testing na Covid richting 2024 . Covid heeft aangetoond dat een precieze diagnose van patiënten steeds belangrijker word ook voor kanker ed. Ziekenhuizen zijn met de pandemie serieus overbelast geweest en hebben standaard ingrepen moeten beperken of verschuiven dan wordt een precieze diagnose zeer belangrijk. PCR testen halen het dan van traditionele methodes en al zeker in tijd . Die markt is zeer snel groeiend en is de core business van Biocartis ( vooral in kanker ) Alleen zien andere bedrijven dit ook en word de lijst met concurrenten heel groot . Biocartis had met zijn technologie een aanzienlijk voordeel op de concurrentie maar om de een of andere reden blijven goedkeuringen van verschillende instanties maar op zich wachten (FDA , Europa , Japan , China ) en wordt de grote doorbraak steeds verder in de tijd geschoven . Dus potentieel ja zeer zeker , komt het er ooit uit : who knowes
Mil That research comes with a relatively steep price tag. There are other research reports that are free that have periodically been posted to this board. There were two sections of the report I'd love to see. The section on MDx moving out of the hospitals and the Appendix presenting assay reimbursement rates. Investors in BCART need to face the fact that NGS systems gets all of the press and the majority of the investment dollars. However, if you read the molecular pathology journal articles you can see that there is a synergy that rapid PCR systems can offer. The MSK presentation of EFGR emphasized this. So I think there will continue to be a place for both technologies. As Gijpie mentioned, I do sense that BCART is at a turning point. The ramp period for launching assays cannot continue to push 3 years. The company realizes this and the FLEX initiative is directed toward expediting the process for content development partners. This is a start. They have shown that they can recognize a problem and move to fix it. They did the same with rectifying the Fisher distribution system issues. The next front I'd like to see progress on is the regulatory personnel to move products from RUO to full IVD approval. I see that many of the positions they are hiring for in the U.S. would include personnel that might help with regulatory approvals. I'm resigned to wait things out another 12 months and reassess the progress at the end of 2021. Hopefully by that time there is more visibility on several fronts including: - the EGFR - Tagrisso CDx -the BMS -Optivo CDx - the China, Japan and US registrations; - the sales ramp of both consoles and cartridges coming out of the pandemic (there should be considerable pent up demand from delayed procedures; -Maybe some news on the Kite gene therapy program would be nice; -Some positive ICU user testimonials on Septicyte Rapid; and -Of course, share price traction. As I have said, the runway for this type of a system could be more than a decade starting at a very low base. Thus BCART could be a great long term holding if they can gain traction and execute. The number of oncology drugs with specific genetic targets grows significantly each year. If BCART can demonstrate to pharma partners that they can secure regulatory approvals for CDx assay products, they will be a sought out partner since they will help the pharma company capture a script before their competitors. Have a Happy New Year! FL
Ik ben eens benieuwd wanneer Biocartis met zijn update gaat komen over het al dan niet halen van de 2020 doelstellingen. Vorig jaar kwam deze op 9 januari. Ik denk / hoop :-) dat deze wel eens kan meevallen: ze gaven in een eerder persbericht bij de CE marking van hun COVID test aan dat deze in de eerste plaats gebruikt zou worden door één van de grootste analysecentra in Londen. Laat Londen nu meteen de plaats zijn waar COVID de laatste maanden van het jaar gigantisch hard toesloeg en waar de ziekenhuizen en ER's vollagen met COVID slachtoffers.
I'd expect a quick update within the next week. Management is on record as saying that BCART is at an inflection point in the growth trajectory. It would be nice if they provide a little visibility as to why they make that statement. Specifically what program/product will drive an uptick in growth. I have been on record as projecting that OncoTypeDx could be a killer App, to a lesser extent Septicyte Rapid and finally EGFR in Asia. To date, one program (Oncotype is dead). ImmunExpress missed their own deadline to release Covid Triage results by the end of 2020 and EGFR is waiting for the first registration approvals in Asia where the mutation is most prevalent. As I mentioned on the board back in Sept. ImmunExpress has demonstrated that Septicyte rapid is equivalent to Septicyte lab. For that reason they should probably garner the FDA approval as occurred in the EU. The Covid Triage study is complicated. The bulk of the data they presented in September suggested some utility for use in triaging Covid patients. But the small dataset indicated there were nagging false positives and false negatives that they could not explain. The problem seems to be that intubation is not necessarily equivalent to sepsis. At the time they did not have access to all of the detailed patient records that might help determine whether the patient actually developed sepsis. Hopefully that has changed. I no longer expect Septicyte Rapid Version 1 to be the Killer Ap we have been looking for. ImmunExpress has a four year collaboration with Novacyt (PrimerDesign) to develop a next generation Sepsis test. This program is pretty secretive as they and their competitor Inflammatix are both pushing hard on developing host-response assays for the ICU. Given the length of the program (since 2017) and the brainpower, this should be a product to really look for. Hopefully, it will be launched on Idylla. So now I'm really looking for more information on the CDx approvals- the EGFR authorization for AZN's - Tasgrisso, MSI for BMS-Optivo-, KRAS for Amgen's product. The gene fusion panel should help with the lung cancer market. The sample size and quality is often limited so it is crucial that the majority of the actionable targets be evaluated from a sample. Gene fusion definitely helps fill out the offerings in the lung cancer area. I would love for BCART to create a little splash and announce the gene fusion assay announcement at JPM. Don't think it will happen but I can dream that things get off to a better 2021 start. It is encouraging that so many presentations were introduced at AMP in November. This indicates that the RUO product is not sitting idle. However, this organic approach will take time. Ultimately, Idylla is competing against well funded giants. It is time to demonstrate traction or be acquired by someone who can better exploit some of the platforms advantages. FL
Today it looks liken the US Senate control will flip to the Democrats as two Trump enabling Senators lose their re-election bids. The big question is whether all the damage can be repaired. The US used to be a force for promoting democracy throughout the world, now we narrowly escape our founding father's worst nightmare. FL
FLat if you think you saw it all he invents the next level
Blijkbaar begint de"stand still" enkelen deftig de keel uit te hangen.Je kan ze geen ongelijk geven!
CGCDLR schreef op 7 januari 2021 10:35 :
Blijkbaar begint de"stand still" enkelen deftig de keel uit te hangen.Je kan ze geen ongelijk geven!
Of zijn er die al meer weten ...
Mij lijkt het een goed instapmoment rond de €4,40...
America is a big and diverse country. The moral center of the country has been shaken, These people who would take attack the Capitol are but a small fringe element. Trump has promised his followers he would "Make America Great" instead he proved that he could incite banana republic behavior. However, despite the chaos of yesterday, steps were taken to secure confidence. The people of Georgia voted out two of Trumps enablers and to that end the Country is truly grateful. Also, Biden's election win was certified guaranteeing that he will be sworn in on the 20th. Now we as a Country must grapple with what actions will be taken against Trump. I suspect that we will find out that the Trump administration conspired with Capitol police to guarantee that they would not resist and in some cases aid the conspirators.. I look forward to a return to normalcy in 2021. FL
@tomtesteron, ze komen met een update op 10/01/2020 of wss maandagmorgen voorbeurs...
Zoals zo vaak bij Biocartis zal er volgens mij zowel positief als negatief nieuws gemeld worden volgende week.Als men kijkt naar de Q3 business update was het cartridgevolume positief en de installed base een tegenvaller. Verwacht voor Q4 hetzelfde. Neemt niet weg dat de huidige koersen meer opportuniteiten bieden dan risico’s.
Wat denkt u eerlijk? Zal deze positief zijn? Koersverloop laatste dagen voorspelt weinig goeds..
Ik verwacht zelf dat ze de doelstellingen voor 2020 behalen mede dankzij hun SARS-CoV-2 test
@Newbie, als Biocartis de verwachtingen naar boven bijsteld voor 2021 dan kan de koers van hieruit 15 à 25% stijgen...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee